Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
03 10 2023
03 10 2023
Historique:
received:
06
04
2023
accepted:
28
07
2023
medline:
4
10
2023
pubmed:
19
8
2023
entrez:
19
8
2023
Statut:
ppublish
Résumé
Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi, formulated for intravenous (IV) and oral administration. This global, multicenter, non-comparative study evaluated the safety and efficacy of fosmanogepix for first-line treatment of candidaemia in non-neutropenic adults. Participants with candidaemia, defined as a positive blood culture for Candida spp. within 96 h prior to study entry, with ≤2 days of prior systemic antifungals, were eligible. Participants received fosmanogepix for 14 days: 1000 mg IV twice daily on Day 1, followed by maintenance 600 mg IV once daily, and optional switch to 700 mg orally once daily from Day 4. Eligible participants who received at least one dose of fosmanogepix and had confirmed diagnosis of candidaemia (<96 h of treatment start) composed the modified intent-to-treat (mITT) population. Primary efficacy endpoint was treatment success at the end of study treatment (EOST) as determined by the Data Review Committee. Success was defined as clearance of Candida from blood cultures with no additional antifungal treatment and survival at the EOST. Treatment success was 80% (16/20, mITT; EOST) and Day 30 survival was 85% (17/20; 3 deaths unrelated to fosmanogepix). Ten of 21 (48%) were switched to oral fosmanogepix. Fosmanogepix was well tolerated with no treatment-related serious adverse events/discontinuations. Fosmanogepix had potent in vitro activity against baseline isolates of Candida spp. (MICrange: CLSI, 0.002-0.03 mg/L). Results from this single-arm Phase 2 trial suggest that fosmanogepix may be a safe, well-tolerated, and efficacious treatment for non-neutropenic patients with candidaemia, including those with renal impairment.
Sections du résumé
BACKGROUND
Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi, formulated for intravenous (IV) and oral administration.
METHODS
This global, multicenter, non-comparative study evaluated the safety and efficacy of fosmanogepix for first-line treatment of candidaemia in non-neutropenic adults. Participants with candidaemia, defined as a positive blood culture for Candida spp. within 96 h prior to study entry, with ≤2 days of prior systemic antifungals, were eligible. Participants received fosmanogepix for 14 days: 1000 mg IV twice daily on Day 1, followed by maintenance 600 mg IV once daily, and optional switch to 700 mg orally once daily from Day 4. Eligible participants who received at least one dose of fosmanogepix and had confirmed diagnosis of candidaemia (<96 h of treatment start) composed the modified intent-to-treat (mITT) population. Primary efficacy endpoint was treatment success at the end of study treatment (EOST) as determined by the Data Review Committee. Success was defined as clearance of Candida from blood cultures with no additional antifungal treatment and survival at the EOST.
RESULTS
Treatment success was 80% (16/20, mITT; EOST) and Day 30 survival was 85% (17/20; 3 deaths unrelated to fosmanogepix). Ten of 21 (48%) were switched to oral fosmanogepix. Fosmanogepix was well tolerated with no treatment-related serious adverse events/discontinuations. Fosmanogepix had potent in vitro activity against baseline isolates of Candida spp. (MICrange: CLSI, 0.002-0.03 mg/L).
CONCLUSIONS
Results from this single-arm Phase 2 trial suggest that fosmanogepix may be a safe, well-tolerated, and efficacious treatment for non-neutropenic patients with candidaemia, including those with renal impairment.
Identifiants
pubmed: 37596890
pii: 7246201
doi: 10.1093/jac/dkad256
pmc: PMC10545531
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Clinical Trial, Phase II
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2471-2480Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Antimicrob Agents Chemother. 2019 Dec 20;64(1):
pubmed: 31611349
Expert Opin Pharmacother. 2021 Jul;22(10):1355-1371
pubmed: 33878996
J Clin Microbiol. 2018 Jan 24;56(2):
pubmed: 29167291
Clin Infect Dis. 2016 Feb 15;62(4):409-17
pubmed: 26810419
Clin Infect Dis. 2020 Dec 3;71(9):e449-e453
pubmed: 32107534
Infection. 2016 Apr;44(2):205-13
pubmed: 26410297
Mycoses. 2020 Apr;63(4):334-342
pubmed: 31997414
Clin Infect Dis. 2019 May 30;68(12):1981-1989
pubmed: 30289478
Antimicrob Agents Chemother. 2011 Oct;55(10):4652-8
pubmed: 21825291
J Antimicrob Chemother. 2019 May 1;74(5):1295-1299
pubmed: 30753499
Lancet Reg Health Am. 2021 Nov 18;6:100117
pubmed: 36777889
Mol Biol Cell. 2003 Oct;14(10):4285-95
pubmed: 14517336
Microorganisms. 2019 Jan 30;7(2):
pubmed: 30704135
Antimicrob Agents Chemother. 2012 Feb;56(2):960-71
pubmed: 22143530
N Engl J Med. 2007 Jun 14;356(24):2472-82
pubmed: 17568028
Clin Infect Dis. 2012 Apr;54(8):1110-22
pubmed: 22412055
Antimicrob Agents Chemother. 2023 May 17;67(5):e0141922
pubmed: 37022196
ACS Chem Biol. 2012 Sep 21;7(9):1520-8
pubmed: 22724584
Antimicrob Agents Chemother. 2020 Oct 20;64(11):
pubmed: 32839219
Clin Microbiol Infect. 2012 Jul;18(7):E246-7
pubmed: 22563750
Ann Clin Microbiol Antimicrob. 2021 May 13;20(1):34
pubmed: 33985505
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Intensive Care Med. 2015 Feb;41(2):285-95
pubmed: 25510301
Clin Infect Dis. 2007 Oct 1;45(7):883-93
pubmed: 17806055
Mycoses. 2008 Sep;51 Suppl 2:46-51
pubmed: 18721331
Antimicrob Agents Chemother. 2015 Jan;59(1):690-2
pubmed: 25331706
Biomed Pharmacother. 2019 Feb;110:857-868
pubmed: 30557835
Clin Infect Dis. 2021 Nov 2;73(9):1609-1616
pubmed: 34079987
Clin Infect Dis. 2021 Dec 6;73(11):e3647-e3655
pubmed: 32955088
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32205345
J Fungi (Basel). 2020 Oct 22;6(4):
pubmed: 33105672
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31182527